EUAA

Identify biomarkers to pair patients with targeted therapies.1

References
IVDR-certified liquid CDx approvals for NSCLC as well as for targeted breast cancer therapy with ESR1 mutations.1

CDx, companion diagnostic; IVDR, In Vitro Diagnostic Regulation; NSCLC, non-small cell lung cancer.
*The efficacy of TAGRISSO® (osimertinib) has not been established in the EGFR T790M plasma-positive, tissue-negative or unknown population and clinical data for T790M plasma-positive patients are limited; therefore, testing using plasma specimens is most appropriate for consideration in patients from whom a tumor biopsy cannot be obtained.¹

TAGRISSO® is a registered trademark of the AstraZeneca group of companies.
RYBREVANT® is a registered trademark of Janssen Biotech, Inc.
LUMAKRASâ„¢ is a trademark of Amgen Inc.
ORSERDUâ„¢ is a trademark of Stemline Therapeutics, a Menarini Group Company.


Product availability may vary depending on region.

Home Oncology Portfolio Partnerships European Policy